Anemia Management News

The British Society of Gastroenterology published guidelines for the management of iron deficiency anemia among an adult population.

Dosis, described in a press release as “a market leader in artificial intelligence-powered precision dosing,” has developed a new tool to personalize anemia management in chronic kidney disease.

The FDA issued a complete response letter to FibroGen indicating it cannot approve the company’s new drug application that seeks approval of roxadustat for anemia of chronic kidney disease.

After more than 7 hours of discussion, the Cardiovascular and Renal Drugs Advisory Committee of the FDA voted against approval of roxadustat for the treatment of anemia due to chronic kidney disease for patients not on dialysis and on dialysis.

A study of patients initiating dialysis in the United States showed that higher levels of lead in the drinking water supply was associated with lower hemoglobin concentrations and greater erythropoietin stimulating agent use.

Iron deficiency was associated with all-cause mortality and major adverse cardiovascular events regardless of whether anemia was also present, results of a multinational study of patients with chronic kidney disease showed.

Patients with chronic kidney disease and iron-deficiency anemia saw statistically significant increases in hemoglobin levels following treatment with oral ferric maltol, according to data from a phase 3 randomized placebo-controlled trial.

Akebia Therapeutics Inc. recently announced the FDA accepted its filing of a new drug application for vadadustat for the treatment of anemia in patients with chronic kidney disease.

Daiichi Sankyo Inc. and American Regent Inc. announced FDA approval of Injectafer, a ferric carboxymaltose injection, for the treatment of adult patients with iron deficiency anemia, according to a press release.

Phase 3 trial results of the anemia drug vadadustat for patients with kidney disease show the drug is efficacious but acknowledge safety issues when used in the non-dialysis patient population.